What stage does Vesalius Biocapital III Partners SàRL invest at?

Vesalius Biocapital III Partners SàRL invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Vesalius Biocapital III Partners SàRL's typical check size?

Vesalius Biocapital III Partners SàRL typically writes checks of $10.8M.

What sectors does Vesalius Biocapital III Partners SàRL focus on?

Vesalius Biocapital III Partners SàRL focuses on Biotech, Digital Health, Healthtech, Medical Devices.

Where is Vesalius Biocapital III Partners SàRL located?

Vesalius Biocapital III Partners SàRL is headquartered in Contern, LU.

Vesalius Biocapital III Partners SàRL

Venture capital

Contern · Seed–Late Stage · 12 people tracked

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

Vesalius Biocapital invests in later-stage life sciences companies across Europe, targeting drug development, medical devices and diagnostics, and eHealth/mHealth (digital health) sectors. The firm looks for portfolio companies that address unmet medical and market needs and are built on strong intellectual property protection. Its active fund, Vesalius Biocapital III, reached a final close in May 2019 with €120 million in commitments.

Invests inBiotech Digital Health Healthtech Medical DevicesAustriaBelgiumDenmarkEuropeFranceGermanyNetherlandsNorwaySwedenSwitzerlandUnited Kingdom

Source: firm website, verified Aug 3, 2026.

Stage

Seed–Late Stage

Check

$10.8M

Contern, LU

Instruments

Equity

Founded

2017

AUM

$132M

Team · 12 people

from the firm's website & public directories

Stéphane Verdood· Managing Partner Fund 1, Fund 2 and Fund 3

Life sciences veteran with over 26 years of experience, Managing Partner across all three Vesalius funds and founder of consultancy Value4Growth. Previously founded and led Arthur Andersen's business consulting division in Belgium and Luxembourg.

Christian Schneider· Managing Partner Fund 1, Fund 2 and Fund 3

Life sciences investor with over 24 years of experience serving as Managing Partner across all three Vesalius funds and lead partner for companies including Activaero and Softhale. Previously invested at PolyTechnos and worked at Roche and Johnson & Johnson.

c•••@vesaliusbiocapital.comreveal

Guy Geldhof· Managing Partner Fund 3 (CFO Fund 1, Partner Fund 2)

Finance leader with over 24 years of experience who has served as CFO, Partner and Managing Partner at Vesalius Biocapital since 2008 and co-founded life sciences consultancy Value4Growth. Formerly at Arthur Andersen and Secretary General of the Belgian Venture Capital and Private Equity Association.

g•••@vesaliusbiocapital.comreveal

Marc Lohrmann· Managing Partner Fund 3

Joined Vesalius Biocapital in 2012 as venture partner and became Managing Partner for Fund 3 in 2017. Co-founded several life sciences companies including Reverse Medical and Softhale, and previously worked at Bayer Innovation and in life sciences M&A.

m•••@vesaliusbiocapital.comreveal

Stephane Verdood· Managing Partner

s•••@vesaliusbiocapital.comreveal

Cees Wortel· Venture Partner Fund 3· Boston

Joined Vesalius Biocapital Fund 3 as Venture Partner. Founded the CRO Clinquest and served as a senior medical research executive at biopharma companies including Centocor, Repligen and Alkermes.

David Braga Malta· Venture Partner Fund 3· Lisbon and Paris

Life sciences entrepreneur and investor who founded Cell2B and BoostPharma and is acting CEO of LiMM Therapeutics. Joined Vesalius Biocapital Fund 3 as Venture Partner after advising Caixa Capital.

Judith Murazishya· Management Assistant

Joined Vesalius Biocapital in 2009 as a management assistant, having previously worked for non-profit organizations.

Martine Goossens· Management Assistant

Joined Vesalius Biocapital in 2012 as a management assistant after working for multinationals such as BNP Paribas Fortis and Kuwait Petroleum.

Pauki Tran· Controller

Joined Vesalius Biocapital in 2012 as a Controller, with prior budget management experience at CNRS and Group ARaymond in France and China.

Virginie Michielsen· Conducting Officer· Luxembourg

Joined Vesalius Biocapital Fund III in 2020 as a Conducting Officer, bringing over 25 years of banking sector experience from BBL/ING and roles at Deloitte Luxembourg and FEDIL.

Fabienne Roussel· Analyst Fund 3

Joined Vesalius Biocapital as an analyst in 2016. A Registered Technology Transfer Professional with a PhD in pharmaco-toxicology and prior experience at Pfizer Central Research and as a patent agent.

f•••@vesaliusbiocapital.comreveal

Frequently asked questions

What stage does Vesalius Biocapital III Partners SàRL invest at?: Vesalius Biocapital III Partners SàRL invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Vesalius Biocapital III Partners SàRL's typical check size?: Vesalius Biocapital III Partners SàRL typically writes checks of $10.8M.
What sectors does Vesalius Biocapital III Partners SàRL focus on?: Vesalius Biocapital III Partners SàRL focuses on Biotech, Digital Health, Healthtech, Medical Devices.
Where is Vesalius Biocapital III Partners SàRL located?: Vesalius Biocapital III Partners SàRL is headquartered in Contern, LU.

Similar investors

Amadeus Capital Partners

Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.

$50K – $12.7M

Capricorn Venture Partners

Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.

$270K – $10.8M

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.

$5M – $25M

EQT Life Sciences

EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.

$11M – $66M

Portfolia

Portfolia operates thematic venture capital funds designed for women investors, backing companies in areas such as women's health, longevity, active aging, greentech, and fintech, while offering an educational and community-driven investing experience.